英派药业-B(07630):IMP1734于2026年ASCO年会公布I/II期临床数据

智通财经
Jun 01

智通财经APP讯,英派药业-B(07630)发布公告,于2026年5月29日至6月2日在美国芝加哥举办的2026年美国临床肿瘤学会(ASCO)年会上,以壁报形式发布高选择性PARP1抑制剂IMP1734(亦称为EIK1003)的最新I/II期临床数据。该壁报(摘要编号:#3102)展示了IMP1734单药治疗及联合紫杉醇治疗晚期实体瘤的安全性与初步有效性数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10